SGLT2i, metformin, or both?

Metformin remains the first-line drug therapy for newly diagnosed type 2 diabetes, while sodium-glucose cotransporter-2(SGLT2) inhibitors are indicated in the presence of established cardiovascular or renal disease or high cardiovascular risk. A study was conducted to determine whether early treatment with an SGLT2 inhibitor alters vascular function and structure in treatment-naive individuals with newly diagnosed T2D by comparing dapagliflozin monotherapy, metformin monotherapy, and their combination.